title: Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture.
abstract: Polyostotic fibrous dysplasia (PFD) is characterized by developmental failure in the remodeling of primitive bone to mature lamellar bone. PFD presents with bone pain, increased bone fragility, deformities, and fractures. Bisphosphonates are the only agents available for medical management.1,2 Intravenous (IV) pamidronate is the established treatment for symptomatic bone involvement in PFD.3,4 Oral alendronate holds promise because of its comparable outcomes, lower cost, and ease of administration.5 The patient described in this case report provided written informed consent for its print and electronic publication after reviewing the complete manuscript and skeletal radiographic images.
authors: Department of Endocrinology, Medwin Hospital, Hyderabad, Andhra Pradesh, India.jmuthukrishnan@hotmail.com
authors: Mathukrishnan
authors: M
authors: Jayaraman
authors: Kvs
authors: K
authors: Karikumar
authors: Abhyuday
authors: A
authors: Verma
authors: Kirtukumar D
authors: KD
authors: Modi
mesh_terms: D000293:Adolescent; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002119:Calcium Carbonate / Q000008:administration & dosage; D002762:Cholecalciferol / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D005359:Fibrous Dysplasia, Polyostotic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D050723:Fractures, Bone / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000209:etiology; D006801:Humans; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D002762:Cholecalciferol; D002119:Calcium Carbonate; D019386:Alendronate